Psilocybin reshapes cortical inhibition through selective interneuron recruitment.
Pasha A Davoudian, Quan Jiang, Cory A Knox, Neil K Savalia, Ling-Xiao Shao, Joshua Wilson, Amanda M Weiner, Catherine W Chong, Clara Liao, Jack D Nothnagel, Takeshi Sakurai, Alex C Kwan
bioRxiv : the preprint server for biology April 17, 2026 DOI: 10.64898/2026.04.16.718963 via PubMed
Summary
AI-generated from the abstractPsilocybin, a classic psychedelic, alters the activity of specific inhibitory neurons in the mouse medial frontal cortex. It reduces firing of somatostatin-expressing interneurons while increasing activity of parvalbumin-expressing interneurons. This cell type-specific response depends on the 5-HT1A receptor on somatostatin interneurons, and contributes to the drug's long-term behavioral effects. The findings reveal that psilocybin changes cortical inhibition in a targeted manner, highlighting a mechanism beyond the commonly studied pyramidal cells.
Study at a glance
| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Mice |
| Intervention | Psilocybin |
| Topics | Depression |
| Keywords | Gabaergic neurons Disinhibition Microcircuit Psychedelic |
| Key finding | Psilocybin reduces firing of somatostatin-expressing interneurons and increases activity of parvalbumin-expressing interneurons in the mouse medial frontal cortex via the 5-HT1A receptor. |
Abstract
Psychedelics show therapeutic potential for treating psychiatric disorders. While studies have emphasized the roles of cortical pyramidal cells, GABAergic neurons also express serotonin receptors and are therefore likely targets of psychedelics. In this study, we determine the effect of psilocybin on the activity dynamics of major GABAergic cell types in the mouse medial frontal cortex. Psilocybin reduces the firing of somatostatin-expressing interneurons, but increases the activity of parvalbumin-expressing interneurons. This cell type-specific response is unlikely to involve vasoactive intestinal peptide-expressing interneurons. Instead, pharmacological blockade and conditional knockout experiments demonstrate that psilocybin acts on the 5-HT1A receptor at SST interneurons, which contributes to the drug's long-term behavioral effects. Collectively, the results reveal that the classic psychedelic psilocybin alters cortical inhibition in a cell type-specific manner.